Biopharmaceutical characterization of decursin and their derivatives for drug discovery

References

• Bleicher KH, Böhm HJ, Müller K, Alanine AI. (2003). Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov, 2:369–378.
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J et al. (2006). Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep, 58:453–472.
   PubMed Web of Science ®Google Scholar
• Li AP. (2001). Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today, 6:357–366.
   PubMed Web of Science ®Google Scholar
• Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE et al. (1999). MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, 88:28–33.
   PubMed Web of Science ®Google Scholar
• Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X et al. (2005). Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther, 313:1254–1262.
   PubMed Web of Science ®Google Scholar
• Kim KM, Kim MJ, Kang JS. (2009). Absorption, distribution, metabolism, and excretion of decursin and decursinol angelate from Angelica gigas Nakai. J Microbiol Biotechnol, 19:1569–1572.
   PubMed Web of Science ®Google Scholar
• Song JS, Chae JW, Lee KR, Lee BH, Choi EJ, Ahn SH et al. (2011). Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica, 41:895–902.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 3:711–715.
   PubMed Web of Science ®Google Scholar
• Mahat B, Chae JW, Baek IH, Song GY, Song JS, Cho SK et al. (2012). Physicochemical characterization and toxicity of decursin and their derivatives from Angelica gigas.Biol Pharm Bull, 35:1084–1090.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bang BH, Han YS, Jun GJ. (2006). A convenient total synthesis of (+)−decursinol from resorcinol. Bull Korean Chem Soc, 27:2104–2106.
   Web of Science ®Google Scholar
• Kang SY, Kim YC. (2007). Decursinol and decursin protect primary cultured rat cortical cells from glutamate-induced neurotoxicity. J Pharm Pharmacol, 59:863–870.
   PubMed Web of Science ®Google Scholar
• Lee YY, Lee S, Jin JL, Yun-Choi HS. (2003). Platelet anti-aggregatory effects of coumarins from the roots of Angelica genuflexa and A. gigas. Arch Pharm Res, 26:723–726.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS. (2003). Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res, 26:727–730.
   PubMed Web of Science ®Google Scholar
• Lee S, Shin DS, Kim JS, Oh KB, Kang SS. (2003). Antibacterial coumarins from Angelica gigas roots. Arch Pharm Res, 26:449–452.
   PubMed Web of Science ®Google Scholar
• Baek IH, Chae JW, Song GY, Kwon KI. (2009). LC–MS/MS Assay validation for a new immune modulator, JHL45, and its major metabolite in plasma: Application to pharmacokinetic studies in rats. Bull Korean Chem Soc, 30:2631–2636.
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and drug administration. Guidance for industry bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (Accessed May 2001)
   Google Scholar
• Herrera MA, Scott OD, Lunte EC. (1990). Microdialysis sampling for determination of plasma protein binding of drugs. Pharm Res, 7:1077–1081.
   PubMed Web of Science ®Google Scholar
• Taylor S, Harker A. (2006). Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal, 41:299–303.
   PubMed Web of Science ®Google Scholar
• Olga VT, Robert GL, John HK, Laurie PV, Gregor Z. Vivid® CYP 450 Screening Kits protocol. Available at: http://tools.invitrogen.com/downloads/O-13873-r1_US_0405.pdf
   Google Scholar
• Trubetskoy OV, Gibson JR, Marks BD. (2005). Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen, 10:56–66.
   PubMed Web of Science ®Google Scholar
• Kuroda S, Takamura F, Tenda Y, Itani H, Tomishima Y, Akahane A et al. (2001). Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. Chem Pharm Bull, 49:988–998.
   PubMed Web of Science ®Google Scholar
• Feng L, Wang L, Jiang X. (2010). Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. Arch Pharm Res, 33:225–230.
   PubMed Web of Science ®Google Scholar
• Mondal KS, Mondal BN, Banarjee S, Mazumder KU. (2009). Determination of drug-like properties of a novel antileishmanial compound: in vitro absorption, distribution, metabolism, and excretion studies. Indian J Pharmacol, 41:176–181.
   PubMed Web of Science ®Google Scholar
• Hill JR. (2004). In vitro drug metabolism using liver microsomes. Curr Protoc Pharmacol, Chapter 7:Unit7.8.
   PubMedGoogle Scholar
• Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masimirembwa CM et al. (2006). Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res, 23:56–69.
   PubMed Web of Science ®Google Scholar
• Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. (1993). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem, 268:14991–14997.
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. (1995). Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT2. J Biol Chem, 70:5672–5677.
   Google Scholar
• Thwaites DT, Hirst BH, Simmons NL. (1993). Passive transepithelial absorption of thyrotropin-releasing hormone (TRH) via a paracellular route in cultured intestinal and renal epithelial cell lines. Pharm Res, 10:674–681.
   PubMed Web of Science ®Google Scholar
• Ranaldi G, Islam K, Sambuy Y. (1992). Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob Agents Chemother, 36:1374–1381.
   PubMed Web of Science ®Google Scholar
• Ranaldi G, Seneci P, Guba W, Islam K, Sambuy Y. (1996). Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines. Antimicrob Agents Chemother, 40:652–658.
   PubMed Web of Science ®Google Scholar
• Rothen-Rutishauser B, Krämer SD, Braun A, Günthert M, Wunderli-Allenspach H. (1998). MDCK cell cultures as an epithelial in vitro model: cytoskeleton and tight junctions as indicators for the definition of age-related stages by confocal microscopy. Pharm Res, 15:964–971.
   PubMed Web of Science ®Google Scholar
• Chen CH. Activation and detoxification enzymes: functions and implications. Biomedical and life sciences. New York, NY, USA: Springer; 2011.
   Google Scholar
• Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. (1989). The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res, 6:71–77.
   PubMed Web of Science ®Google Scholar
• Madgula VL, Avula B, Reddy V L N, Khan IA, Khan SI. (2007). Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Planta Med, 73:330–335.
   PubMed Web of Science ®Google Scholar
• Kratochwil NA, Huber W, Müller F, Kansy M, Gerber PR. (2002). Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol, 64:1355–1374.
   PubMed Web of Science ®Google Scholar